Observational prospective cohort (n=140) collecting real-world safety and tolerability data on ketamine treatment (IV, intranasal, oral) in adult psychiatric inpatients with a range of diagnoses including MDD, PTSD, OCD and others.
This prospective observational registry collects systematic real-world data on ketamine administration in a tertiary inpatient psychiatry service to evaluate safety, tolerability and patient-reported outcomes across diverse clinical presentations.
Treatments include slow IV infusions (0.5 mg/kg over 40 minutes), intranasal spray, and oral solution (2.0–2.5 mg/kg), administered twice weekly for 4 weeks; adverse events, vitals and longer-term outcomes are documented to inform clinical practice.
Real-world ketamine treatment delivered via IV infusion, intranasal spray, or oral solution across diagnostic cohorts in an inpatient tertiary centre.
Slow IV infusion 0.5 mg/kg over 40 minutes, twice weekly for 4 weeks (8 sessions).
Intranasal ketamine spray twice weekly for 4 weeks (dose not specified).
Oral solution 2.0–2.5 mg/kg twice weekly for 4 weeks.